Trospium Chloride XR in Obese Female Patients With Overactive Bladder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
La Mesa, California, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- OAB syndrome with Urgency, Urinary frequency and Urgency urinary incontinence
- Non-smoker (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the screening visit).
- Obese
Exclusion Criteria:
- Chronic kidney failure
- Abdominal bypass surgery for obesity
- Moderate or severe memory impairment
- Uncontrolled narrow angle glaucoma
- Uncontrolled systemic disease
- Concurrent dementia drugs: Aricept (donepezil), Namenda (memantine), Cognex (tacrine), Exelon (rivastigmine), Razadyne (galantamine), or similar drugs for dementia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: trospium chloride XR 60 mg
Placebo capsule taken orally once daily for 2 weeks followed by trospium chloride extended release (XR) 60 mg capsule taken orally once daily for 12 weeks.
|
Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.
Other Names:
Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
|
|
Placebo Comparator: placebo
Placebo capsule taken orally once daily for 14 weeks.
|
Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent Change From Baseline in Urinary Urgency Incontinence (UUI)
Time Frame: Baseline (Week 2), Week 14
|
Patients recorded information about UUI (accidental leakage, urgency associated with void and urgency severity) in a 3-day diary at Baseline (Week 2) and Week 14.
The daily average episodes of UUI was the sum of all UUI episodes over valid diary days during the 3-day diary period divided by the valid number of diary days with at least one valid bladder entry.
The percent change from baseline was calculated as (Mean UUI at Week 14- Mean UUI at Week 2)/ Mean UUI at Week 2 X 100.
A negative number percent change from baseline indicated an improvement.
|
Baseline (Week 2), Week 14
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent Change From Baseline in Urgency Severity Associated With Toilet Voids
Time Frame: Baseline (Week 2), Week 14
|
Due to lack of evaluable data, analysis for this outcome measure was not performed.
|
Baseline (Week 2), Week 14
|
|
Percent Change From Baseline in Voided Volume
Time Frame: Baseline (Week 2), Week 14
|
Due to lack of evaluable data, analysis for this outcome measure was not performed.
|
Baseline (Week 2), Week 14
|
|
Percent Change From Baseline in Over Active Bladder (OAB)-Symptom Composite Score
Time Frame: Baseline (Week 2), Week 14
|
Due to lack of evaluable data, analysis for this outcome measure was not performed.
|
Baseline (Week 2), Week 14
|
|
Percent Change From Baseline in Percentage of Patients Continent
Time Frame: Baseline (Week 2), Week 14
|
Due to lack of evaluable data, analysis for this outcome measure was not performed.
|
Baseline (Week 2), Week 14
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Diseases
- Urinary Bladder Diseases
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Urinary Bladder, Overactive
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Urological Agents
- Trospium chloride
Other Study ID Numbers
Other Study ID Numbers
- MA-SXR-09-003
- Sanctura XR obesity OAB Trial (Other Identifier: Allergan)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.